Medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 8th that it attended the 'Korea-China Venture Startup Summit' held as part of President Lee Jae-myung's visit to China as a representative Korean unicorn company.
Hosted by the Ministry of SMEs and Startups and held at the Shanghai International Exhibition Center in China, the summit was attended by approximately 400 people, including President Lee Jae-myung, Chief of Staff to the President Kim Yong-beom, Deputy Prime Minister and Minister of Science and ICT Bae Kyung-hoon, Minister of SMEs and Startups Han Sung-sook, Chinese Ambassador to Korea, Korean Ambassador to China, Deputy Mayor of Shanghai, and other government officials from both countries, as well as representatives from major tech companies and the investment industry.
Seo Beom-seok, CEO of Runit, participated in the ‘Dialogue with Korean and Chinese Venture Startups’ session chaired by the President, and presented his opinions on the direction of cooperation and tasks to be promoted as a representative unicorn company of both countries, along with Chinese unicorn company BrainCo.
In his presentation, CEO Seo mentioned the growth potential of the Chinese AI healthcare market and explained that discussions are underway regarding the possibility of utilizing AI biomarkers, which are being jointly researched and developed with global pharmaceutical companies, in the Chinese market when they are launched as companion diagnostics (CDx) in the future.
In response, President Lee Jae-myung expressed his agreement that synergy would be achieved by combining China's market size and speed with Korea's technological reliability and stability, and expressed his willingness to provide government-level support.
After the summit, CEO Seo also attended the Korea-China Investment Conference and the Global Fund Inauguration Ceremony, where he met with venture capital firms and other investment firms and discussed ways to expand sales channels and cooperation with promising Chinese companies.
Lunit entered the Chinese market in 2020 by establishing a subsidiary, Lunit China, in Shanghai. Since then, it has been supplying AI products in research and laboratory environments through global partners with branches in China, including Agilent, LabCorp, Cellcarta, Roche Diagnostics, and IndicaLabs. Furthermore, it has attracted investment from major investors in China and the Greater China region, including Regent Capital and Taiburn Capital, and continues its partnerships.
- See more related articles
You must be logged in to post a comment.